Novartis scores 3 points higher than Roche Holding on SINK.
Novartis is more sustainable according to SINK's scores, scoring 52/100 vs Roche Holding's 49/100, a difference of 3 points.
Novartis scores 52/100 on SINK (Making progress). Novartis cut its emissions to 4.36 MtCO2e in 2025, with Scope 1 and 2 down 45% and Scope 3 down 17% against 2022, under SBTi-validated targets for net zero by 2040. Its electricity is 100% renewable, though only 49% of all its energy is. Its waste rose in 2025, its 'carbon neutral' claim rests on removal credits and certificates, and old chemical landfills near Basel are still being cleaned up.
Roche Holding scores 49/100 on SINK (Making progress). Roche has achieved strong operational decarbonisation (46% S1&2 reduction since 2022) and received SBTi validation for net-zero targets — a pharma first. However, nature and biodiversity assessment remains absent, water targets lack absolute reduction commitments, and significant non-environmental regulatory penalties ($433M since 2000) persist alongside VCI trade association misalignment.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard: 1,023 companies ranked.
View the full leaderboard →